Cadrenal Therapeutics Statistics
Total Valuation
CVKD has a market cap or net worth of $6.94 million. The enterprise value is $4.40 million.
| Market Cap | 6.94M |
| Enterprise Value | 4.40M |
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CVKD has 2.87 million shares outstanding. The number of shares has increased by 50.99% in one year.
| Current Share Class | 2.87M |
| Shares Outstanding | 2.87M |
| Shares Change (YoY) | +50.99% |
| Shares Change (QoQ) | +13.41% |
| Owned by Insiders (%) | 14.84% |
| Owned by Institutions (%) | 6.13% |
| Float | 2.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.38 |
| P/TBV Ratio | 3.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.68
| Current Ratio | 2.68 |
| Quick Ratio | 2.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -300.59% and return on invested capital (ROIC) is -190.38%.
| Return on Equity (ROE) | -300.59% |
| Return on Assets (ROA) | -139.24% |
| Return on Invested Capital (ROIC) | -190.38% |
| Return on Capital Employed (ROCE) | -670.38% |
| Weighted Average Cost of Capital (WACC) | 13.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.38M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.27% in the last 52 weeks. The beta is 1.75, so CVKD's price volatility has been higher than the market average.
| Beta (5Y) | 1.75 |
| 52-Week Price Change | -81.27% |
| 50-Day Moving Average | 4.26 |
| 200-Day Moving Average | 7.64 |
| Relative Strength Index (RSI) | 30.61 |
| Average Volume (20 Days) | 96,310 |
Short Selling Information
The latest short interest is 82,016, so 2.86% of the outstanding shares have been sold short.
| Short Interest | 82,016 |
| Short Previous Month | 72,278 |
| Short % of Shares Out | 2.86% |
| Short % of Float | 3.36% |
| Short Ratio (days to cover) | 1.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.05M |
| Pretax Income | -11.89M |
| Net Income | -11.89M |
| EBITDA | -12.05M |
| EBIT | -12.05M |
| Earnings Per Share (EPS) | -$5.57 |
Balance Sheet
The company has $2.31 million in cash and n/a in debt, with a net cash position of $2.31 million or $0.80 per share.
| Cash & Cash Equivalents | 2.31M |
| Total Debt | n/a |
| Net Cash | 2.31M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 1.80M |
| Book Value Per Share | 0.72 |
| Working Capital | 1.79M |
Cash Flow
In the last 12 months, operating cash flow was -$10.96 million and capital expenditures -$1,853, giving a free cash flow of -$10.96 million.
| Operating Cash Flow | -10.96M |
| Capital Expenditures | -1,853 |
| Depreciation & Amortization | 1,912 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.96M |
| FCF Per Share | -$3.82 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CVKD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -50.99% |
| Shareholder Yield | -50.99% |
| Earnings Yield | -177.13% |
| FCF Yield | -163.25% |
Analyst Forecast
The average price target for CVKD is $27.67, which is 1,043.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $27.67 |
| Price Target Difference | 1,043.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |